Skip to main content

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Completed · Phase 4 · NCT06634797

Conditions: Healthy Volunteers

At a glance

Research payments reported, 2025
$972,458
U.S. investigators named
24
Sites paid
1
Planned or actual enrollment
1,000

About the trial

Sponsor
ModernaTX, Inc.
Tested
mRNA-1273.712 (biological), Placebo (biological)
Dates
Started 2024-10-08; completion 2025-01-20
Results posted
Yes

The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.

From ClinicalTrials.gov, last updated 2026-02-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

ModernaTX, Inc. reported $972,458 in research payments for this study in 2025 (92 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Velocity Clinical Research Inc $972,458

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.